Johns Hopkins University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Johns Hopkins University sits in the top decile of US sponsors by registered trial count (#14 of 15,742 sponsors by registered trial count).

1,448 total trials 250 currently recruiting 943 completed early-phase tilt top decile by trial count

Johns Hopkins University: 1,448 sponsored US clinical trials, 250 recruiting.

Johns Hopkins University sponsors 1,448 registered US clinical trials on ClinicalTrials.gov, 250 of them currently recruiting, and 943 completed. 125 of these trials are in Phase 3-4 (later-stage) and 399 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertension, with 15 trials.

Top-decile sponsor footprint

Johns Hopkins University ranks in the top decile of sponsors by registered trial count (#14 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 52/100

943 of 1,108 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,448 total, page 16 of 29

COMPLETED NA

Lamina Cribrosa Depth Change With Change in Eye Pressure

NCT03267849
COMPLETED Phase 2

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

NCT03450083
TERMINATED Phase 4

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

NCT03006562
COMPLETED Phase 4

Oral Sedation During Cervical Dilator Placement

NCT03202550
COMPLETED

Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

NCT03196492
COMPLETED NA

Financial Incentives to Reduce Pediatric Tobacco Smoke Exposures

NCT03099811
COMPLETED NA

The IPV Provider Network: Engaging the Health Care Provider Response to Interpersonal Violence Against Women

NCT03259646
COMPLETED NA

COach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation

NCT03142932
COMPLETED NA

Vouchers to Increase Uptake of Already Free Eye Care

NCT04426331
COMPLETED

Medication Adherence Research in COPD Patients

NCT03174704
TERMINATED NA

Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation

NCT03143894
COMPLETED Phase 1

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

NCT03100045
COMPLETED NA

An EPIC Based BPA to Enhance Quit Line Referral and Use

NCT03229356
COMPLETED NA

Impact of a Peer Support Program Amongst COPD Patients and Their Caregivers

NCT02891200
COMPLETED NA

Procalcitonin for Stewardship in Respiratory Infections A Stewardship Project

NCT03109106
TERMINATED Early Phase 1

Trial of Orencia in Patients With Myasthenia Gravis

NCT03059888
COMPLETED NA

Physical Activities by Technology Help (PATH)

NCT03212079
COMPLETED

Assessment of Primary Oxygenation and Airflow Measurement for Endoscopic Laryngeal Surgery

NCT03222869
COMPLETED Phase 2

Ramelteon in the Prevention of Post-operative Delirium

NCT02324153
COMPLETED NA

Behavioral Therapy for Tourette Syndrome

NCT03019731
TERMINATED Phase 2

Celecoxib for Thyroid Eye Disease

NCT02845336
COMPLETED NA

Can we Train Patients With Chronic Stroke Out of Abnormal Hand Synergy?

NCT03255590
COMPLETED Phase 2

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

NCT02792257
COMPLETED Phase 2

Propranolol for Sleep Apnea Therapy

NCT03049306
COMPLETED Phase 1

The FIGHT-RP1 Study

NCT03063021
COMPLETED NA

IPC for University Counseling Centers

NCT03255954
COMPLETED NA

Improving Identification of Mental Health/Substance Use Disorders in HIV Primary Care: Pilot Clinical Response

NCT03067948
COMPLETED NA

Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

NCT03294616
TERMINATED Phase 1

Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence

NCT01011777
COMPLETED NA

Notation Optimization Through Template Engineering

NCT04333238
COMPLETED NA

Sugar Champ: Pilot Social Network Intervention to Reduce Intake of Sugary Drinks

NCT02138240
TERMINATED

Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy

NCT02875704
COMPLETED NA

Cognitive Behavior Therapy for Insomnia (CBT-I) in Persons With Traumatic Brain Injury (TBI)

NCT02709980
COMPLETED

The Center for Peripartum Optimization

NCT03522909
COMPLETED NA

Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.

NCT03027063
COMPLETED NA

Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections

NCT03021668
COMPLETED Phase 1

Study of Tofacitinib in Refractory Dermatomyositis

NCT03002649
COMPLETED Phase 4

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013
TERMINATED NA

Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes

NCT02212652
COMPLETED Phase 2

A Novel Biologic Therapy for Perennial Allergic Rhinitis

NCT03360071
COMPLETED

Early Peanut Introduction: Translation to Clinical Practice

NCT03019328
COMPLETED Phase 2

Enhancing Medication-based Analgesia in Humans

NCT02901275
TERMINATED NA

Sleep Disruption in Post-operative Patients in the Neurocritical Care Unit

NCT02997839
COMPLETED NA

Rapid HIV Treatment Initiation, Access and Engagement in Care

NCT03512964
COMPLETED NA

Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes

NCT02896010
COMPLETED NA

Myocardial Infarction, COmbined-device, Recovery Enhancement Study

NCT03760796
COMPLETED Phase 1

Optimization of a Tenofovir Enema for HIV Prevention

NCT02750540
COMPLETED NA

Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program

NCT02927821
COMPLETED NA

Patient Engagement Initiative

NCT02721810
COMPLETED NA

Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment

NCT02901574
← Previous Page 16 of 29 Next →

Phase Distribution

PhaseTrial count
Phase 1 201
Phase 2 198
Phase 3 44
Phase 4 81

Therapeutic Areas

Hypertension 15
Depression 12
HIV 11
Stroke 10
HIV Infections 8
Mild Cognitive Impairment 7
Dementia 7
Alzheimer Disease 7
Asthma 6
Insomnia 6

What is open in the Johns Hopkins University pipeline

250 recruiting of 1,448 indexed (17% open); 943 completed (65%).

Phase mix: 125 late (III/IV) vs 399 early (I/II) (early-phase heavy).

Top condition: Hypertension (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Johns Hopkins University: open-pipeline peers nationwide

Peers matched on 1,448 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Johns Hopkins University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Johns Hopkins UniversityUniversity of PennsylvaniaYale UniversityWashington University School of MedicineNovartis PharmaceuticalsSeattle Children's HospitalHunter College of City University of New YorkOchsner Health SystemVirginia Polytechnic Institute and State University
Johns Hopkins University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Johns Hopkins University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,448 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Johns Hopkins University page

1,448 registered trials is a research-attention snapshot, not an endorsement of Johns Hopkins University or any single study.

  • 250 of Johns Hopkins University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypertension is the condition Johns Hopkins University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertension trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Johns Hopkins University pipeline card: 1,448 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.